よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


11【参考資料1-6】9価HPVワクチンファクトシート (48 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_29181.html
出典情報 厚生科学審議会予防接種・ワクチン分科会(第41回 11/18)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

2056

176. Mejilla, A., et al. (2017). Human papilloma virus (HPV) vaccination: Questions and

2092

of Gynecologic Oncology Guideline. J Gynecol Oncol 30(2): e31.

2057

answers.Can Pharm J (Ott). 150: 306-315.

2093

https://www.ncbi.nlm.nih.gov/pubmed/30740959

2058

https://www.ncbi.nlm.nih.gov/pubmed/28894500

2094

189. Jiang, Y., et al. (2019). Cost-effectiveness and value-based prices of the 9-valent human

2059

177.

2095

papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling

2060

https://www.healthlinkbc.ca/healthlinkbc-files/hpv-vaccines

2061

178.

2062

British Colombia HealthLink BC.(2019). Human Papillomavirus (HPV) Vaccines.

2096

analysis. BMJ Open 9(11): e031186. https://www.ncbi.nlm.nih.gov/pubmed/31767588

2097

190. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019:

https://www.merck.ca/static/pdf/GARDASIL_9-PM_E.pdf

2098

conclusions and recommendations. (2019).

Merck

Canada

Inc.

(2020).

PRODUCT

MONOGRAPH

GARDASIL®9.

2063

179. Public Health Agency of Canada.(2019). Public Health Agency of Canada. Canadaʼs

2099

Weekly Epidemiological Record. 2019, 94, 541‒560.

2064

Provincial and Territorial Routine (and Catch-up) Vaccination Schedule for Infants and

2100

https://www.who.int/wer/2019/wer9447/en/

2065

Children. https://www.canada.ca/content/dam/phac-aspc/documents/services/provincial-

2101

191.

2066

territorial-immunization-information/childhood-vaccination-schedule-august-2019.pdf

2102

(2019). 19th meeting of the European Technical Advisory Group of Experts on immunization

2067

180.

Patel, C., et al. (2018). The impact of 10 years of human papillomavirus (HPV)

2103

(ETAGE) (2019).

2068

vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

2104

https://www.euro.who.int/__data/assets/pdf_file/0009/424647/ETAGE-2019-report.pdf

2069

Euro Surveill 23(41).

2105

2070

181.

2071

Papillomavirus(HPV).(2018). Factsheet Human Papillomavirus(HPV).

2072

http://ncirs.org.au/ncirs-fact-sheets-faqs/human-papillomavirus-vaccine-australians

2073

182. Merck Sharp & Dohme (Australia) Pty Limited. (2017). PRODUCT INFORMATION

2074

GARDASIL®9. https://www.tga.gov.au/sites/default/files/auspar-human-papillomavirus-9-

2075

valent-vaccine-170103-pi.pdf

2076

183.

2077

(2017). Introduction of GARDASIL® 9 In a 2-Dose Schdule under the School-based National

The European Technical Advisory Group of Experts on Immunization (ETAGE).

National Centre for Immunisation Research and Surveillance. Factsheet Human

Australian Technical Advisory Group on Immunisation (ATAGI). Clinical Advice.

2078

Immunisation Program (NIP). https://www.health.gov.au/sites/default/files/atagi-advice-

2079

gardasil9.pdf

2080

184. The New Zealand Ministry of Health.HPV vaccine.

2081

https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-

2082

immunisation-programme/hpv-vaccine

2083

185. The Immunisation Advisory Centre . Gardasil 9 Schedule and administration.

2084

https://www.immune.org.nz/vaccines/available-vaccines/gardasil-9

2085

186.

2086

SHEET GARDASIL® 9

Merck Sharp & Dohme (New Zealand) Limited. (2019).NEW ZEALAND DATA

2087

https://www.medsafe.govt.nz/profs/Datasheet/g/gardasil9inj.pdf

2088

187.

2089

Introduction of Vaccination to the National Immunization Program in Korea: an Overview. J

Kim, M. A., et al. (2018). Current Status of Human Papillomavirus Infection and

2090

Korean Med Sci 33(52): e331.

2091

188. Min, K. J., et al. (2019). Clinical guideline for 9-valent HPV vaccine: Korean Society

95

96